Kontrol’s COVID-19 Technology Receives Positive Lab Results for Live COVID-19 Testing
Kontrol Energy Corp. has announced positive lab results for its Kontrol BioCloud technology, successfully testing against the live COVID-19 virus. Following previous tests on the dormant SARS-CoV-2 virus, the company is shifting its focus to commercialization, targeting CSA Group approval within 30 to 45 days. Kontrol aims for a manufacturing capacity of up to 20,000 units per month. This innovative technology is designed to monitor air quality and detect airborne viruses in various public settings, although no claims are made regarding its effectiveness against COVID-19.
- Positive lab results for BioCloud technology against live COVID-19 virus.
- Commencing commercialization process with CSA Group approval anticipated in 30-45 days.
- Plans for manufacturing capacity of up to 20,000 BioCloud units per month.
- No revenue projections provided for BioCloud technology.
- Kontrol BioCloud a Safe Space Technology™ -
TORONTO, ON / ACCESSWIRE / September 10, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) ("Kontrol" or "Company") is pleased to provide an update on its Kontrol BioCloud (or "BioCloud") technology.
Lab Testing with Live Virus
Kontrol has received positive lab results for BioCloud testing against the live virus that causes COVID-19. This positive result follows two successful tests against the dormant SARS-CoV-2 virus (see press release dated August 10th, 2020 and press release dated August 27th, 2020).
"We are very pleased that through a methodical approach we have been able to successfully test our technology with the live virus causing COVID-19 and will turn our focus to commercialization of BioCloud," says Paul Ghezzi, CEO of Kontrol. "It has been a long journey to get to this point since the initial concept design in March 2020 and through the great efforts of our team we look forward to delivering a safe space technology solution."
"This technology can improve our surveillance of SARS-CoV-2 by monitoring air quality in
multiple settings."
Dr. Jimmy D. Dikeakos, Ph.D
"This technology will allow for measurement of many different viruses, bacteria, and fungi beyond the immediate need for the virus that causes COVID-19."
Dr. David Heinrichs, Ph.D
Commercialization
Kontrol will begin the commercialization process of BioCloud by initiating an application to the CSA Group. CSA is a leader in Standards Development and in Testing, Inspection and Certification around the world including Canada, the U.S., Europe and Asia. The CSA registered mark shows that a product has been independently tested and certified to meet recognized standards for safety or performance. Kontrol anticipates that a CSA approval can take from 30 to 45 days to complete and Kontrol has a history of working with CSA on various air quality and emission products. During the process of CSA approval, Kontrol will seek to establish lower detection limits of the COVID-19 virus. Lower detection limit specifications are part of the commercial specifications that Kontrol will deliver for a fully commercialized product.
"We are very pleased to start the process of sharing our technology with the market through the commencement of commercialization," says Gary Saunders, VP of Kontrol. "We want to thank our lab partners for all of their expertise and dedication. The lab procedures involved significant planning and preparation to execute meticulous testing against the live COVID-19 virus. We look forward to sharing our results with all levels of Government in the coming days and weeks ahead."
Manufacturing Capacity
Kontrol has commenced discussions with two global outsource contract manufacturers who can provide Kontrol with external manufacturing capacity. Kontrol is not making any statements or assumptions about potential revenues, however, Kontrol is planning for up to 20,000 BioCloud units per month as manufacturing capacity. This is part of Kontrol's prudent overall planning and access to manufacturing capability.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Kontrol Energy is one of Canada's fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean's.
|
|
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.
 |  |  |
For further information, contact:
Paul Ghezzi, Chief Executive Officer
paul@kontrolenergy.com or admin@kontrolenergy.com
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company's product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol's lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
SOURCE: Kontrol Energy Corp.
View source version on accesswire.com:
https://www.accesswire.com/605663/Kontrols-COVID-19-Technology-Receives-Positive-Lab-Results-for-Live-COVID-19-Testing
FAQ
What were the lab results for Kontrol's BioCloud technology?
What is the timeline for Kontrol's BioCloud commercialization?
How many BioCloud units does Kontrol plan to manufacture?
Does Kontrol make any claims about its BioCloud technology's effectiveness against COVID-19?
